Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.

@article{Dummer2018EncorafenibPB,
  title={Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.},
  author={Reinhard Dummer and Paolo Antonio Ascierto and Helen J. Gogas and Ana M Arance and Mario Mandal{\`a} and Gabriella Liszkay and Claus Garbe and Dirk Schadendorf and Ivana Krajsov{\'a} and Ralf Gutzmer and Vanna Chiarion-Sileni and Caroline Dutriaux and Jan Willem B. de Groot and Naoya Yamazaki and Carmen Loquai and Laure A Moutouh-de Parseval and Michael D. Pickard and Victor Sandor and Caroline Robert and Keith T. Flaherty},
  journal={The Lancet. Oncology},
  year={2018},
  volume={19 5},
  pages={603-615}
}
BACKGROUND Combined BRAF-MEK inhibitor therapy is the standard of care for BRAFV600-mutant advanced melanoma. We investigated encorafenib, a BRAF inhibitor with unique target-binding properties, alone or in combination with the MEK inhibitor binimetinib, versus vemurafenib in patients with advanced BRAFV600-mutant melanoma. METHODS COLUMBUS was conducted as a two-part, randomised, open-label phase 3 study at 162 hospitals in 28 countries. Eligible patients were aged 18 years or older and had… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 35 times. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 14 extracted citations

Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2018
View 4 Excerpts
Highly Influenced

Encorafenib and Binimetinib: First Global Approvals

Drugs • 2018
View 10 Excerpts
Highly Influenced

Interleukin-1 Beta—A Friend or Foe in Malignancies?

International journal of molecular sciences • 2018
View 1 Excerpt

MEK inhibitors for the treatment of NRAS mutant melanoma

Drug design, development and therapy • 2018
View 1 Excerpt

Similar Papers

Loading similar papers…